FibroBiologics, Inc. (FBLG) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FibroBiologics, Inc. (FBLG) trades at $1.29 with AI Score 24/100 (Grade F). FibroBiologics, Inc. is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies. Market cap: $2.70M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 4, 2026Analyst Coverage for FBLG: FBLG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FBLG against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FBLG: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
FibroBiologics, Inc. (FBLG) Healthcare & Pipeline Overview
FibroBiologics, Inc. is a clinical-stage biotechnology company specializing in fibroblast-based therapies for degenerative diseases, multiple sclerosis, and wound healing. With a focus on regenerative medicine, the company aims to address unmet needs through innovative cell therapy solutions and early-stage research in related fields.
What Is the Investment Thesis for FBLG?
FibroBiologics, Inc. presents a notable research candidate within the burgeoning cell therapy market. The company's focus on fibroblast-based therapies offers a differentiated approach to regenerative medicine, with potential applications across multiple disease areas. Key value drivers include the advancement of its clinical-stage programs, particularly CybroCell for degenerative disc disease, which addresses a significant unmet need. Successful clinical trials and regulatory approvals could drive substantial revenue growth. Furthermore, the company's early-stage research programs offer long-term growth potential. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established players in the biotechnology industry. As of 2026, the company's market capitalization is $0.00B, reflecting its early stage of development.
Based on FMP financials and quantitative analysis
FBLG Key Highlights
FibroBiologics is a clinical-stage company focused on fibroblast-based therapies, a novel approach in regenerative medicine.
- The company's lead product, CybroCell, targets degenerative disc disease, a large and underserved market.
- FibroBiologics has a pipeline of therapies in development for multiple sclerosis (CYMS101) and wound healing (CYWC628).
- Early-stage research programs include potential treatments for thymus/spleen regeneration, psoriasis, and certain cancers.
- The company is headquartered in Houston, Texas, and was incorporated in 2021.
Who Are FBLG's Competitors?
FBLG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MESO Mesoblast Limited | $17.49 | +2.10% | $2.27B | 65 |
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FBLG's Key Strengths?
Novel fibroblast-based therapy platform.
- Pipeline of therapies targeting unmet medical needs.
- Experienced management team with expertise in regenerative medicine.
- Strong intellectual property portfolio.
What Are FBLG's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Small number of employees.
What Could Drive FBLG Stock Higher?
Clinical trial results for CybroCell in degenerative disc disease (2027).
- Initiation of Phase 2 clinical trials for CYMS101 in multiple sclerosis (2026).
- Regulatory submissions for CYWC628 in wound healing (2028).
- Advancement of early-stage research programs in thymus/spleen regeneration, psoriasis, and certain cancers.
- Strategic partnerships and collaborations to expand research and development capabilities.
What Are the Key Risks for FBLG?
Financial-distress signal — its Altman Z-Score of -17.62 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for its lead product candidates.
- Regulatory delays or rejections.
- Competition from established biotechnology companies.
- Dependence on securing additional funding to support its operations.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for FBLG?
- Expansion of CybroCell into new indications: FibroBiologics has the opportunity to expand the application of CybroCell beyond degenerative disc disease to address other spinal disorders and musculoskeletal conditions. The market for spinal implants and regenerative therapies is estimated to reach $10 billion by 2030. Successful clinical trials and regulatory approvals for new indications could significantly increase CybroCell's market potential.
- Advancement of CYMS101 for multiple sclerosis: Multiple sclerosis is a chronic autoimmune disease affecting millions worldwide. FibroBiologics' CYMS101 therapy has the potential to address the underlying causes of MS by modulating the immune system and promoting myelin regeneration. The global market for MS therapies is projected to reach $30 billion by 2028. Positive clinical trial results and regulatory approval could position CYMS101 as a leading treatment option.
- Commercialization of CYWC628 for wound healing: Chronic wounds represent a significant healthcare burden, affecting millions of patients with diabetes, vascular disease, and other conditions. FibroBiologics' CYWC628 therapy aims to accelerate wound healing by promoting fibroblast proliferation and collagen synthesis. The market for advanced wound care products is estimated to reach $22 billion by 2027. Successful clinical trials and regulatory approval could enable FibroBiologics to capture a significant share of this market.
- Strategic partnerships and collaborations: FibroBiologics can leverage strategic partnerships and collaborations to accelerate its research and development efforts, expand its manufacturing capabilities, and access new markets. Collaborations with academic institutions, biotechnology companies, and pharmaceutical companies can provide access to valuable resources and expertise. These partnerships can also help to de-risk the development process and increase the likelihood of success.
- Expansion into new therapeutic areas: FibroBiologics has the opportunity to expand its pipeline of fibroblast-based therapies into new therapeutic areas, such as autoimmune diseases, cardiovascular diseases, and cancer. The company's early-stage research programs in thymus/spleen regeneration, psoriasis, and certain cancers represent potential growth opportunities. Successful preclinical and clinical studies could lead to the development of innovative therapies for these diseases.
What Are FBLG's Competitive Advantages?
- Proprietary fibroblast-based therapy platform.
- Patent protection for its therapies and technologies.
- Clinical data supporting the safety and efficacy of its products.
- Expertise in regenerative medicine and cell therapy.
What Does FBLG Do?
FibroBiologics, Inc., incorporated in 2021 and headquartered in Houston, Texas, is a clinical-stage cell therapy company dedicated to the development and commercialization of fibroblast-based therapies. The company's core focus lies in leveraging the unique properties of fibroblasts to address unmet medical needs in various therapeutic areas. FibroBiologics is actively developing a pipeline of innovative treatments, including CybroCell for degenerative disc disease, CYMS101 for multiple sclerosis, and CYWC628 for wound healing. These therapies are designed to harness the regenerative potential of fibroblasts to restore tissue function and improve patient outcomes. In addition to its clinical-stage programs, FibroBiologics is engaged in early-stage research on several promising candidates, including CYTER915 for thymus and spleen regeneration, CYPS317 for psoriasis, and TCB190 for certain cancers. The company's research and development efforts are centered on advancing the science of fibroblast-based therapies and expanding their applications across a range of diseases. FibroBiologics aims to establish itself as a leader in the field of regenerative medicine through its commitment to innovation, scientific excellence, and patient-centric drug development.
What Products and Services Does FBLG Offer?
- Develops fibroblast-based therapies for various diseases.
- Focuses on regenerative medicine and cell therapy.
- Creates treatments for degenerative disc disease (CybroCell).
- Develops therapies for multiple sclerosis (CYMS101).
- Creates therapies for wound healing (CYWC628).
- Conducts early-stage research for thymus and spleen regeneration (CYTER915).
- Researches treatments for psoriasis (CYPS317).
- Explores therapies for certain cancers (TCB190).
How Does FBLG Make Money?
- Develops and patents fibroblast-based therapies.
- Conducts preclinical and clinical trials to evaluate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved therapies through direct sales or partnerships.
What Industry Does FBLG Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in cell and gene therapies, personalized medicine, and regenerative medicine. FibroBiologics operates in a competitive landscape, with established biotechnology companies and emerging players vying for market share. Key competitors include companies developing cell therapies for similar indications. The company's success will depend on its ability to differentiate its fibroblast-based therapies, secure regulatory approvals, and establish strategic partnerships.
Who Are FBLG's Key Customers?
- Patients suffering from degenerative disc disease.
- Patients with multiple sclerosis.
- Individuals with chronic wounds.
- Potential future patients with autoimmune diseases, cardiovascular diseases, and cancer.
Financial Health
FibroBiologics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.62 places it in the distress zone, a signal of elevated financial risk.
FibroBiologics, Inc. (FBLG) Valuation Context
Valued at $2.70M, FBLG is classified as a micro-cap stock. Relative to its peer group, FBLG's quantitative score of 24/100 is below the peer average of 66/100.
Company Profile
FibroBiologics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Peter O'Heeron. FBLG has traded publicly since 2024.
Forward Outlook
Wall Street analysts project FibroBiologics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-4.01.
FBLG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- FibroBiologics shows promising insider confidence; recent activity indicates strong belief in the company's direction.
- The community buzz is largely positive, with excitement around potential applications of their core technology.
- Market perception is shifting towards regenerative medicine, and FibroBiologics is well-positioned to capitalize on this trend.
- There's a growing narrative that FibroBiologics' unique approach could disrupt existing treatment paradigms.
Bear Case
- Insider activity, while positive overall, has some selling activity that raises questions about short-term expectations.
- Community sentiment, although mostly bullish, shows concerns about the timeline for commercialization.
- The market is competitive; other players in regenerative medicine could overshadow FibroBiologics' progress.
- Skepticism exists regarding the scalability of their technology and its ability to meet market demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FBLG Latest News
-
Snap To Rally More Than 217%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga · Aug 4, 2026
FBLG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FBLG.
Price Targets
Wall Street price target analysis for FBLG.
FBLG MoonshotScore
What does this score mean?
The MoonshotScore rates FBLG 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Peter O'Heeron
CEO
Peter O'Heeron is the CEO of FibroBiologics, Inc. He brings extensive experience in managing and leading teams within the biotechnology sector. His background includes a strong focus on strategic development and operational execution. He is responsible for overseeing the company's overall strategy, including research and development, clinical trials, and commercialization efforts. His leadership is crucial in guiding FibroBiologics through its clinical stages and towards potential market entry.
Track Record: Under Peter O'Heeron's leadership, FibroBiologics has advanced its pipeline of fibroblast-based therapies, including CybroCell, CYMS101, and CYWC628. He has overseen the initiation and progression of clinical trials, as well as the expansion of the company's research and development programs. His strategic decisions have been instrumental in positioning FibroBiologics as a key player in the regenerative medicine field.
What Investors Ask About FibroBiologics, Inc. (FBLG) — Healthcare
What does the AI Score mean for FBLG?
FBLG holds an AI Score of 24/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. FibroBiologics, Inc. is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies. Their pipeline includes treatments for degenerative disc disease …
What does FibroBiologics, Inc. Common Stock do?
FibroBiologics, Inc. is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies. The company's primary focus is on regenerative medicine, utilizing fibroblasts to address unmet medical needs in areas such as degenerative disc disease, multiple sclerosis, and wound healing.
What do analysts say about FBLG stock?
As of May 4, 2026, there is limited analyst coverage available for FibroBiologics, Inc. (FBLG), likely due to its clinical-stage nature and relatively recent incorporation in 2021. Key valuation metrics are still developing, and the company's growth prospects are tied to the successful advancement of its clinical programs.
What are the main risks for FBLG?
The main risks for FibroBiologics, Inc. stem from its status as a clinical-stage biotechnology company. These include the potential for clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining approvals for its therapies also pose a significant risk.
What are the key factors to evaluate for FBLG?
FibroBiologics, Inc. (FBLG) holds an AI score of 24/100 (low). presents a notable research candidate within the burgeoning cell therapy market. Not financial advice.
How frequently does FBLG data refresh on this page?
FBLG's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FBLG's recent stock price performance?
FibroBiologics, Inc. (FBLG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel fibroblast-based therapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBLG overvalued or undervalued right now?
FibroBiologics, Inc. (FBLG) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FBLG before investing?
Before investing in FibroBiologics, Inc. (FBLG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited publicly available data.
- Financial metrics are estimates due to the company's early stage.
- Clinical trial outcomes are inherently uncertain.